Grace Therapeutics grants director 12,200 options

A Grace Therapeutics director received 12,200 stock options at a $2.13 exercise price with vesting over one year.

Rhea-AI Filing Summary

Grace Therapeutics, Inc. (GRCE) reported that director Brian A. Davis received a grant of stock options covering 12,200 shares of Common Stock on September 17, 2026. The options have an exercise price of $2.13 per share and expire on September 16, 2036.

According to the vesting terms, 50% of the option vests on the grant date and the remaining 50% vests in substantially equal monthly installments over 12 months, subject to his continuous service. After this grant, he holds 12,200 options directly. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 0 shares

Grant/Award 1 txn

Insider DAVIS A BRIAN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	--	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 12,200 contracts (Direct)

Footnotes (1)

1. F1. 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date.

Key Figures

Stock options granted: 12,200 options Exercise price: $2.13 per share Post-grant option holdings: 12,200 options +2 more

5 metrics

Stock options granted 12,200 options Grant to director Brian A. Davis on September 17, 2026

Exercise price $2.13 per share Exercise price for the 12,200 stock options

Post-grant option holdings 12,200 options Total options held by Brian A. Davis after the reported grant

Vesting schedule 50% immediate, 50% over 12 months Vesting terms for the 12,200 stock options, subject to continuous service

Option expiration date September 16, 2036 Expiration date for the granted stock options

Key Terms

Stock Option, exercise price, vesting, Common Stock

4 terms

Stock Option financial

"grant of stock options covering 12,200 shares of Common Stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The options have an exercise price of $2.13 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"grant of stock options covering 12,200 shares of Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GRCE report for Brian A. Davis?

Grace Therapeutics reported that director Brian A. Davis received a grant of stock options for 12,200 shares of Common Stock on September 17, 2026, as a compensation-related award.

What is the exercise price of the new stock options granted at GRCE?

The stock options granted to Brian A. Davis have an exercise price of $2.13 per share, meaning he can purchase Grace Therapeutics Common Stock at that price upon exercise, subject to vesting and other terms.

How many Grace Therapeutics options does Brian A. Davis hold after this Form 4?

After the reported grant, Brian A. Davis holds 12,200 stock options related to Grace Therapeutics Common Stock, all reported as directly owned.

What is the vesting schedule for the 12,200 GRCE stock options?

According to the disclosure, 50% of the option vests on the grant date, and the remaining 50% vests in substantially equal monthly installments over a 12‑month period, subject to his continuous service on each vesting date.

When do Brian A. Davis’s GRCE stock options expire?

The granted stock options related to Grace Therapeutics Common Stock expire on September 16, 2036, if they are not exercised earlier and subject to the terms of the award.

Was the GRCE option grant to Brian A. Davis made under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with this option grant to Brian A. Davis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 04:21 PM Accepted by SEC EDGAR 09/21/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DAVIS A BRIAN

(Last) (First) (Middle)

C/O GRACE THERAPEUTICS, INC.

103 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Grace Therapeutics, Inc. [ GRCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.13	09/17/2026		A		$12,200		(1)	09/16/2036	Common Stock	12,200	$0	12,200	D

Explanation of Responses:

1. 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date.

	/s/ Robert DelAversano as attorney-in-fact for A. Brian Davis	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)